A Phase 1 interventional study of BMS-962212 and Aspirin in Thrombosis, sponsored by Bristol-Myers Squibb. Completed at 3 sites in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-07-02.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing aspirin in Thrombosis — 2 open to participants now, 3 under way, none of them phase 3. Aspirin · Thrombosis.
Among the 28 studies testing aspirin in Thrombosis, this one is the 5th largest by enrollment, is one of 3 that started in 2013, is one of 4 in phase 1, and was the 22nd registered.
955 studies on the registry are indexed under Thrombosis; 171 are open to participants now.
Browse Thrombosis studies →2 of the 28 studies testing aspirin in Thrombosis are open now, in 2 countries. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18+
Zealand University Hospital · Sites in Denmark
Ages 18–85
By country, each count listing its studies:
Aspirin: first FDA approval 1950 (PERCODAN), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 126 Thrombosis studies recruiting now, 79 (63%) set no upper age limit and 16 (13%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 691 is above the median of 83 across 530 interventional studies indexed under Thrombosis.
Median enrollment 106 across the 28 interventional studies. Of the 19 that completed or were terminated, 8 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 28 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
19 studies in Thrombosis by Bristol-Myers Squibb: none open now, none under way, none of them phase 3. Of 19 finished, 7 (37%) have results posted.
Among the 19 studies in Thrombosis by Bristol-Myers Squibb, this one has the largest enrollment, is the only one that started in 2013, is one of 13 in phase 1, and was the 14th registered.
Bristol-Myers Squibb’s Thrombosis studies by the year they started, since 2006.
2 of the studies testing aspirin in Thrombosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04330729Zealand University HospitalThe Effect of Salicylate on Platelet Function in CKD (Chronic Kidney Disease) Patients Treated With Aranesp | 2026-12-31 |
| NCT07613840Massachusetts General HospitalPersonalizing Thromboprophylaxis for Patients With Peripheral Artery Disease | 2027-04-29 |
Add all 2 to your calendar (.ics) → With an account.
Among the 28 studies testing aspirin in Thrombosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 19 in Thrombosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics following increasing doses of 2 h (Part A) and 5 day (Part B) continuous IV infusions of BMS-962212 in healthy subjects across the expected pharmacodynamic dose range.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intravenous administered over 2 hours of BMS-962212
Drug: BMS-962212
Intravenous administered over 5 days of BMS-962212
Drug: BMS-962212
BMS-962212 intravenous administration, followed by aspirin oral administration, then combination administration of BMS-962212 and aspirin
Drug: BMS-962212 · Drug: Aspirin
Placebo intravenous administration, followed by aspirin, then combination administration of placebo and aspirin
Drug: Aspirin · Other: Placebo
Placebo intravenous administration
Other: Placebo
Intravenous Infusion administration over 2 hours or 5 days
Oral administration
Oral administration
Adverse Events (AE)
measured by incidence
Time frame: Up to 8 days
Serious Adverse Events (SAE)
measured by incidence
Time frame: Up to 8 days
Discontinuation due to AE
measured by incidence
Time frame: Up to 8 days
Death
measured by incidence
Time frame: Up to 8 days
AE of clinically significant bleeding
measured by incidence
Time frame: Up to 8 days
AE of clinically significant infusion reaction
measured by incidence
Time frame: Up to 8 days
AE of clinically significant vital signs
measured by incidence
Time frame: Up to 8 days
QTcF intervals - QT interval corrected for heart rate according to Fridericia's formula
measured by ECG
Time frame: Up to 8 days
QRS - The interval from the beginning of the Q wave and the end of the S wave
measured by ECG
Time frame: Up to 8 days
PR - The interval from the beginning of the P wave to the beginning of the QRS complex
measured by ECG
Time frame: Up to 8 days
24-hour cardiac monitoring
measured by telemetry
Time frame: Up to 6 days
Glomerular filtration rate (GFR)
measured by iohexol administration plasma clearance and the Chronic Kidney Disease-Epidemiology Collaborative Group (CKD EPI) equation
Time frame: Up to 8 days
Cystatin-C
measured by serum biomarkers
Time frame: Up to 8 days
Neutrophil gelatinase-associated lipocalin (NGAL)
measured by urine biomarkers
Time frame: Up to 8 days
Monocyte chemoattractant protein-1 (MCP-1)
measured by urine biomarkers
Time frame: Up to 8 days
Ran from Nov 2013 to primary completion in Feb 2016, 26 months.
Of 30 phase 1 interventional studies under Thrombosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 30. This study's 26 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aspirin